Edwards Lifesciences Corporation (EWL)
XETRA Stock Exchange · Germany · prices in EUR · close of 23 Oct 2026
Key indicators
| Last close | EUR 79.94 |
|---|---|
| 52-week range | 63.38 – 84.00 |
| Return, 1 month / 3 months | +3.3% / +8.0% |
| Return, 1 year / 3 years | – / – |
| Trend | Uptrend |
| RSI (14) | 64 |
| Volatility (1 year) | 27.6% |
| Worst drawdown (1 year) | -16.0% |
| Average daily value traded | 0.01M EUR |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Edwards Lifesciences Corporation develops medical devices for heart disease, with a focus on heart valves and hemodynamic monitoring. Its transcatheter heart valve systems let physicians replace valves through minimally invasive procedures, while its surgical valve products serve patients needing open-heart operations. The company also supplies monitoring and critical care technologies used in hospitals and clinics. It is based in Irvine, California, and its customers are mainly hospitals, cardiac surgeons, cardiologists and healthcare providers around the world.
The shares are listed on the XETRA Stock Exchange in Germany under the code EWL, and the price on this page is in euros (EUR). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Edwards Lifesciences Corporation (EWL) trades on the XETRA Stock Exchange in Germany. It last closed at EUR 79.94 on 23 October 2026.
Its price-based Market X-Ray is 68 out of 100 (a fair price profile), ranking 143 of 701 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on XETRA Stock Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 76 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 8.4% | ||
| From 52-week high | -3.7% | ||
| Momentum | 77 · Strong | Rising faster than most stocks on this exchange. | |
| 3-month return | 8.0% | ||
| 6-month return | 17.2% | ||
| 12-month return, skipping the last month | – | ||
| Stability (higher is calmer) | 81 · Strong | Calmer than most: low volatility and shallow drawdowns. | |
| Volatility, 1 year (lower is calmer) | 27.6% | ||
| Worst drawdown, 1 year (smaller is calmer) | -16.0% | ||
| Liquidity | 14 · Weak | Thinly traded: prices can jump and exits can be hard. | |
| Average daily value traded | 0.01M EUR | ||
| Zero-volume days | 0.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 0 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Momentum: Rising faster than most stocks on this exchange.
- Stability (higher is calmer): Calmer than most: low volatility and shallow drawdowns.
Weak spots
- Liquidity: Thinly traded: prices can jump and exits can be hard.
Returns
| 1 week | +3.5% |
|---|---|
| 1 month | +3.3% |
| 3 months | +8.0% |
| 6 months | +17.2% |
| 1 year | – |
| 3 years | – |
| 5 years | – |
Signals
| 50-day / 200-day average | 76.96 / 73.75 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 1.20 |
Technical summary
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on XETRA Stock Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.